DOCSLIB.ORG

BTS Guideline for Bronchiectasis in Adults Has Been Endorsed By

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BTS Guideline for Bronchiectasis in Adults Has Been Endorsed By January 2019 Volume 74 Supplement 1 AnThorax international journal of RESPIRATORY MEDICINE BRITISH THORACIC SOCIETY GUIDELINE FOR BRONCHIECTASIS IN ADULTS British Thoracic Society Bronchiectasis in Adults Guideline Development Group thorax.bmj.com BTS Bronchiectasis in Adults Guideline Development Group Professor Adam T Hill, Dr Anita L Sullivan, Professor James D Chalmers, Professor Anthony De Soyza, Professor J Stuart Elborn, Professor R Andres Floto, Ms Lizzie Grillo, Dr Kevin Gruffydd-Jones, Ms Alex Harvey, Dr Charles S Haworth, Mr Edwin Hiscocks, Dr John R Hurst, Dr Christopher Johnson, Dr W Peter Kelleher, Dr Pallavi Bedi, Miss Karen Payne, Mr Hesham Saleh, Dr Nicholas J Screaton, Dr Maeve Smith, Professor Michael Tunney, Dr Deborah Whitters, Professor Robert Wilson, Professor Michael R Loebinger On behalf of the British Thoracic Society The BTS Guideline for Bronchiectasis in Adults has been endorsed by: Association for Chartered Physiotherapists in Respiratory Care Association of Respiratory Nurse Specialists Primary Care Respiratory Society UK Royal College of Physicians London Healthcare providers need to use clinical judgement, knowledge and expertise when deciding whether it is appropriate to apply recommendations for the management of patients. The recommendations cited here are a guide and may not be appropriate for use in all situations. The guidance provided does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of each patient, in consultation with the patient and/or their guardian or carer. 74 January 2019 Volume 74 Supplement 1 S1 Volume 74 Supplement 1 Volume Contents Volume 74 Supplement 1 | THORAX January 2019 Pages 1–69 Pages ThoraxAn international journal of RESPIRATORY MEDICINE BRITISH THORACIC SOCIETY GUIDELINE FOR BRONCHIECTASIS 1 Summary of recommendations and good 15 Tests for specific disease groups with associated THORAX IN ADULTS British Thoracic Society practice points bronchiectasis Bronchiectasis in Adults Guideline Development Group 15 Allergic bronchopulmonary aspergillosis January 2019 January Section 1 16 Immune dysfunction 10 Introduction 16 Serum immunoglobulins (IgG, IgA, & IgM) and thorax.bmj.com 10 Target audience for the guideline electrophoresis 10 Scope of the guideline Journal of the British Thoracic Society 16 Full blood count (FBC) 10 Areas not covered by the guideline 16 Measurement of baseline specific antibody Impact Factor: 9.655 10 Definition Editors-in-Chief levels against capsular polysaccharides of N Hart (UK) Streptococcus pneumonia G Jenkins (UK) Section 2 Rheumatoid Arthritis AR Smyth (UK) 10 Methodology 17 Deputy Editors Recurrent aspiration 10 Clinical Questions and Literature Search 17 N Kaminski (USA) 17 Cystic fibrosis M Rosenfeld (USA) 10 Appraisal of Literature Ciliary dysfunction Associate Editors 11 Considered Judgement and Grading of Evidence 17 D Baldwin (UK) J-L Pepin (France) 18 Young’s syndrome R Chambers (UK) M Polkey (UK) 11 Drafting the Guideline T Coleman (UK) J Quint (UK) 18 Alpha-1 antitrypsin deficiency GJ Criner (USA) N Rahman (UK) 11 Guideline Group Members and Declarations of J Davies (UK) K Robinson (USA) Interest 18 Congenital Causes A Floto (UK) S Shaheen (UK) 18 Investigations of lung microbiology M Griffiths (UK) R Stevens (USA) 11 Stakeholders L Heaney (UK) A Vonk Noordegraaf N Hopkinson (UK) (The Netherlands) Section 7 S Janes (UK) C Wainwright (Australia) Section 3 B Kampman (UK) T Wilkinson (UK) 19 Prognosis: What is the outlook for these patients? B Mohkelesi (USA) P Wolters (USA) 11 How common is bronchiectasis? Section 8 Statistical Editors Section 4 A Douiri (UK) 19 Severity scoring C Flach (UK) 12 How should the diagnosis of bronchiectasis C Jackson (UK) be determined? S Stanojevic (USA) Section 9 R Szczesniak (USA) 12 Imaging 20 Stable state treatment B Wagner (USA) 20 Airway clearance techniques Y Wang (UK) Section 5 Which patients should be taught airway Journal Club Editor 12 In whom should the diagnosis of bronchiectasis 20 P Murphy (UK) be suspected? clearance techniques? President, British Thoracic Society 21 Adherence Dr M Elliott 13 COPD Which airway clearance techniques should be Editorial Office 13 Alpha-1 antitrypsin deficiency (A1AT) 21 Thorax, BMA House, Tavistock Square, taught? London WC1H 9JR, UK 13 Asthma How often should patients carry out airway T: +44 (0)20 7383 6373 13 Rhinosinusitis 24 E: [email protected] clearance techniques? How long should an airway 13 Chronic systemic infection Twitter: @ThoraxBMJ clearance session last? 13 Rheumatoid arthritis ISSN: 0040-6376 (print) 24 How soon should the patient be reviewed after ISSN: 1468-3296 (online) 13 Other connective tissue diseases the initial assessment? Disclaimer: Thorax is owned and published by the 13 Inflammatory bowel disease British Thoracic Society and BMJ Publishing Group 24 Mucoactives in bronchiectasis Ltd, a wholly owned subsidiary of the British Medical Association. The owners grant editorial freedom to 25 What is the evidence for long term anti-inflammatory the Editor of Thorax. Section 6 Thorax follows guidelines on editorial independence 14 Investigations for causes of bronchiectasis therapies in bronchiectasis? produced by the World Association of Medical Editors and the code on good publication practice 14 Standard laboratory tests of the Committee on Publication Ethics. MORE CONTENTS Thorax is intended for medical professionals and is provided without warranty, express or implied. Statements in the Journal are there sponsibility of their authors and advertisers and not authors’ institutions, the BMJ Publishing Group Ltd, the British Thoracic Society or theBMAunless otherwise This article has been chosen by the Editors to be of special interest specified or determined by law. Acceptance of or importance and is freely available online. advertising does not imply endorsement. To the fullest extent permitted by law, the BMJ This article has been made freely available online under the BMJ Publishing Group Ltd shall not be liable for any loss, injury or damage resulting from the use of Thorax Journals Open Access scheme. or any information in it whether based on contract, See http://authors.bmj.com/open-access/ tort or otherwise. Readers are advised to verify any information they choose to rely on. Copyright: © 2019 BMJ Publishing Group Ltd and This journal is a member of and subscribes to the principles of the the British Thoracic Society. All rights reserved; no COPE Committee on Publication Ethics part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or Member since 2009 http://publicationethics.org/ by any means, electronic, mechanical, photocopying, JM03979 recording or otherwise without the prior permission of Thorax. Thorax is published by BMJ Publishing Group Ltd, typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper. Thorax (ISSN No: 0040–6376) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431. POSTMASTER: send address changes to Thorax, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Contents Volume 74 Supplement 1 | THORAX January 2019 27 What treatments improve outcomes for patients Section 18 with stable bronchiectasis? 46 Specialist vs non-specialist setting 30 Does long term bronchodilator treatment improve outcomes for patients with bronchiectasis? Section 19 31 Pulmonary Rehabilitation 46 What are the complications of bronchiectasis? Inspiratory Muscle Training 32 Section 20 Field Walking Tests 32 47 Summary of research recommendations 33 What is the role of surgery in managing bronchiectasis? Tables 33 Lung transplantation for bronchiectasis Table 1 Quick Summary Guide 34 What is the role of influenza and pneumococcal Table 2 Levels of evidence vaccination in management of bronchiectasis Table 3 Grades of recommendation 35 Treatment of respiratory failure Table 4 Variables involved in calculating the severity 36 Bronchiectasis and other treatments score in the Bronchiectasis Severity Index Table 5 Variables involved in calculating severity in Section 10 the FACED score Do pathogens have an impact on prognosis in 36 Table 6 Common organisms associated with bronchiectasis? acute exacerbation of bronchiectasis and Section 11 suggested antimicrobial agents- adults 37 What is the evidence for the role of viruses/ Table 7 Routine monitoring tests fungal disease in patients with bronchiectasis? Figures Section 12 4 Figure 1 Management of the deteriorating patient 37 Does eradication of potentially pathogenic 5 Figure 2 Stepwise management microorganisms improve outcomes in patients 26 Figure 3 Physiotherapy management-stepwise with stable bronchiectasis? airway clearance 26 Figure 4 Airway clearance – exacerbation Section 13 43 Figure 5 Algorithm for initial assessment and 38 Exacerbations treatment – rhinosinusitis 38 Does antibiotic therapy improve outcomes in patients with an exacerbation of bronchiectasis? Appendices 55 Appendix 1: Guideline group members Section 14 55 Appendix 2: Protocol for test dose of a nebulised 40 Specific treatments antibiotic 40 What treatments improve outcomes in patients 55 Appendix 3: Long term antibiotic regimes with bronchiectasis and ABPA? 56 Appendix 4: Specialist immunology investigations 41 Does immunoglobulin replacement treatment 59 Appendix 5: Summary table of papers for improve outcomes in
Load more

Recommended publications
  • SIGN158 British Guideline on the Management of Asthma
    SIGN158 British guideline on the management of asthma A national clinical guideline First published 2003 Revised edition published July 2019 Key to evidence statements and recommendations Levels of evidence 1++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1+ Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1– Meta-analyses, systematic reviews, or RCTs with a high risk of bias 2++ High-quality systematic reviews of case-control or cohort studies High-quality case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal 2+ Well-conducted case-control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal 2– Case-control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal 3 Non-analytic studies, eg case reports, case series 4 Expert opinion Grades of recommendation Note: The grade of recommendation relates to the strength of the supporting evidence on which the evidence is based. It does not reflect the clinical importance of the recommendation. A At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target population; or A body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results B A body of evidence including studies rated
    [Show full text]
  • Appendix on Tariff Elimination Schedule for Mercosur
    Trade part of the EU-Mercosur Association Agreement Without Prejudice Disclaimer: In view of the Commission's transparency policy, the Commission is publishing the texts of the Trade Part of the Agreement following the agreement in principle announced on 28 June 2019. The texts are published for information purposes only and may undergo further modifications including as a result of the process of legal revision. However, in view of the growing public interest in the negotiations, the texts are published at this stage of the negotiations for information purposes. These texts are without prejudice to the final outcome of the agreement between the EU and Mercosur. The texts will be final upon signature. The agreement will become binding on the Parties under international law only after completion by each Party of its internal legal procedures necessary for the entry into force of the Agreement (or its provisional application). AR applied BR applied PY applied UY applied Mercosur Final NCM Description Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 01022911 Other bovine animals for breeding,pregnant or lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 01023911 Other buffalo for breeding, ex.
    [Show full text]
  • A Professional Development Framework for Paediatric Respiratory Nursing
    A professional development framework for paediatric respiratory nursing ISSN 2040-2023: British Thoracic Society Reports Vol 12, Issue 2, May 2021 1 ACKNOWLEDGEMENTS: We are grateful to colleagues at the National Paediatric Respiratory and Allergy Nurses Group (NPRANG) for their support with the development of this document. In particular: Ann McMurray Asthma Nurse Specialist, Royal Hospital for Children and Young People, Edinburgh. NPRANG Chair Bethan Almeida Clinical Nurse Specialist for Paediatric Asthma and Allergy, Imperial College Healthcare NHS Trust Tricia McGinnity Paediatric Cystic Fibrosis Nurse Specialist, Southampton Children's Hospital Emma Bushell Paediatric Respiratory Nurse Specialist – Asthma, Frimley Health NHS Foundation Trust This document has been adapted from the following publication: British Thoracic Society, A professional development framework for respiratory nursing (1). The authors of this original document are: Samantha Prigmore, Co-chair Consultant respiratory nurse, St Georges University Hospitals NHS Foundation Trust Helen Morris, Co-chair ILD nurse specialist, Wythenshawe Hospital Alison Armstrong Nurse consultant (assisted ventilation), Royal Victoria Infirmary Susan Hope Respiratory nurse specialist, Royal Stoke University Hospital Karen Heslop-Marshall Nurse consultant, Royal Victoria Infirmary Jacqui Pollington Respiratory nurse consultant, Rotherham NHS Foundation Trust CONTENTS: Introduction Method of production How to use this document Competency table (Band 5, 6, 7 and 8) Supporting evidence Acknowledgements Declarations of Interest References Content from this document may be reproduced with permission from BTS as long as you conform to the following conditions: • The text must not be altered in any way. • The correct acknowledgement must be included. 2 Introduction Paediatric respiratory nurses are an important component of the multi-professional team for a wide variety of respiratory conditions, providing holistic care for patients in a variety of settings.
    [Show full text]
  • Drug Consumption in 2017 - 2020
    Page 1 Drug consumption in 2017 - 2020 2020 2019 2018 2017 DDD/ DDD/ DDD/ DDD/ 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital ATC code Subgroup or chemical substance day % day % day % day % A ALIMENTARY TRACT AND METABOLISM 322,79 3 312,53 4 303,08 4 298,95 4 A01 STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01A STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01AA Caries prophylactic agents 11,90 3 10,48 4 8,42 5 8,45 7 A01AA01 sodium fluoride 11,90 3 10,48 4 8,42 5 8,45 7 A01AA03 olaflur 0,00 - 0,00 - 0,00 - 0,00 - A01AB Antiinfectives for local oral treatment 2,36 8 2,31 7 2,31 7 2,02 7 A01AB03 chlorhexidine 2,02 6 2,10 7 2,09 7 1,78 7 A01AB11 various 0,33 21 0,21 0 0,22 0 0,24 0 A01AD Other agents for local oral treatment 0,02 0 0,03 0 0,04 0 - - A01AD02 benzydamine 0,02 0 0,03 0 0,04 0 - - A02 DRUGS FOR ACID RELATED DISORDERS 73,05 3 71,13 3 69,32 3 68,35 3 A02A ANTACIDS 2,23 1 2,22 1 2,20 1 2,30 1 A02AA Magnesium compounds 0,07 22 0,07 22 0,08 22 0,10 19 A02AA04 magnesium hydroxide 0,07 22 0,07 22 0,08 22 0,10 19 A02AD Combinations and complexes of aluminium, 2,17 0 2,15 0 2,12 0 2,20 0 calcium and magnesium compounds A02AD01 ordinary salt combinations 2,17 0 2,15 0 2,12 0 2,20 0 A02B DRUGS FOR PEPTIC ULCER AND 70,82 3 68,91 3 67,12 3 66,05 4 GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 0,17 7 0,74 4 1,10 4 1,11 5 A02BA02 ranitidine 0,00 1 0,63 3 0,99 3 0,99 4 A02BA03 famotidine 0,16 7 0,11 8 0,11 10 0,12 9 A02BB Prostaglandins 0,04 62
    [Show full text]
  • 17Th & 18Th June 2021 Speakers' Details and Presentation Summaries
    th th SUMMER MEETING ONLINE – 17 & 18 June 2021 Speakers’ Details and Presentation Summaries The following details are in programme order. Use the PDF search button to quickly find a session or speaker. OPEN SESSION – NATIONAL ASTHMA AND COPD AUDIT PROGRAMME Thursday 17th June: 08:00-09:00 Dr James Calvert qualified in Medicine from Oxford Session aims and overview University in 1992. He studied Public Health as a 1) To summarise the main findings of the 2020/21 Fulbright Scholar at Harvard University before NACAP reports. completing his PhD in Asthma Epidemiology in South 2) To outline the QI support opportunities offered by Africa and London. NACAP to clinical and audit teams. He was a Consultant Respiratory Specialist in Bristol from 2006-2021. He is now a Respiratory Consultant Professor Roberts will present a summary of key and Medical Director of Aneurin Bevan University reported findings from across the audits from the last Health Board in Wales. 12 months, highlighting areas for further James has worked with colleagues in the South West improvement. He will speak about the impact of and at NHS England to improve access to integrated COVID-19 on standards of care and on audit services for respiratory patients. He has Chaired the participation, along with plans to improve automated British Thoracic Society (BTS) Professional and extraction of NACAP data. Organisational Standards Committee and has been Dr Calvert will talk about the QI programme to be the BTS National Audit Lead. He has a longstanding launched this year. interest in quality improvement in health care and has A discussion will follow around ideas for improving worked with the BTS, NHS Improving Value, the Royal NACAP support to clinical and audit teams.
    [Show full text]
  • A Bibliometric Analysis
    787 Original Article Page 1 of 9 The 100 most cited articles on lung cancer screening: a bibliometric analysis Meng Li1,2, Qiang Cai2,3, Jing-Wen Ma1, Li Zhang1,2, Claudia I. Henschke2 1Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; 2Department of Radiology, Mount Sinai Health System, New York, NY, USA; 3Department of Radiology, Shanxi Provincial People’s Hospital, Taiyuan, China Contributions: (I) Conception and design: M Li, CI Henschke; (II) Administrative support: CI Henschke; (III) Provision of study materials or patients: M Li, CI Henschke; (IV) Collection and assembly of data: M Li, L Zhang; (V) Data analysis and interpretation: M Li, Q Cai, JW Ma; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Claudia I. Henschke. Department of Radiology, Mount Sinai Health System, 1 Gustave Levy Place, New York, NY 10029, USA. Email: [email protected]. Background: The number of citations of an article reflects its impact on the scientific community. The aim of this study was to identify and characterize the 100 most cited articles on lung cancer screening. Methods: The 100 most cited articles on lung cancer screening published in all scientific journals were identified using the Web of Science database. Relevant data, including the number of citations, publication year, publishing journal and impact factor (IF), authorship and country of origin, article type and study design, screening modality, and main topic, were collected and analyzed. Results: The 100 most cited articles were all English and published between 1973 and 2017, with 81 published after 2000.
    [Show full text]
  • Non-Pharmacologic Therapies and Airway Clearance Techniques in Bronchiectasis
    Division of Pulmonary, Critical Care and Sleep Medicine NON-PHARMACOLOGIC THERAPIES AND AIRWAY CLEARANCE TECHNIQUES IN BRONCHIECTASIS Ashwin Basavaraj, MD, FCCP Associate Director, NYU Bronchiectasis Program NTM Patient Education Program DC 11/24/2019 October 30, 2019 Financial Disclosure • Insmed - Consultant, Advisory Board (Active) • Hill-Rom – Consultant, Principal investigator on a clinical trial (Active) • COPD foundation grant on airway clearance 2 Division of Pulmonary, Critical Care and Sleep Medicine DC 11/24/2019 Case presentation • 66 year-old female with a history of prior pneumonia 15 years ago presents with productive cough. • She has mild shortness of breath. No fevers, no hemoptysis. She has gained two pounds over the year. • No other prior medical history, and currently not taking any medications • Initial workup including autoimmune serologies and quantitative immunoglobulin levels were negative. • You check AFB, bacterial and fungal sputum cultures. • She has 2 out 3 cultures positive for MAC. 3 Division of Pulmonary, Critical Care and Sleep Medicine DC 11/24/2019 4 Division of Pulmonary, Critical Care and Sleep Medicine DC 11/24/2019 What’s the next best step in management? A) Start 3 drug antibiotic therapy for MAC B) Initiate airway clearance with nebulized hypertonic saline and a positive expiratory pressure device C) Start antibiotics for MAC and initiate airway clearance D) Closely monitor without initiation of treatment 5 Division of Pulmonary, Critical Care and Sleep Medicine DC 11/24/2019 GOALS OF AIRWAY CLEARANCE Short term goals Long term goals • Provide more effective sputum • Reduce further airway damage by clearance that improves ventilation halting the vicious cycle • Reduce cough and breathlessness • Reduce pulmonary exacerbations • Improve quality of life O’Neill, et al.
    [Show full text]
  • Management of Breathlessness in Patients with Life Limiting Disease
    MANAGEMENT OF BREATHLESSNESS IN PATIENTS WITH LIFE LIMITING DISEASE Helen Armstrong Dr Helen Bonwick Dr Clare Jeffries Dr Martin Ledson Dr Kate Marley Mrs Sue Oakes CURRENT STANDARDS AND GUIDELINES • Current standards and guidleines • Literature review – pharmacological and non- pharmacological • Audit results • Proposed new standards and guidelines • Current management of cough Guidelines Non pharmacological options (Level 4 ) • These are important and should not be overlooked. They may be used alone or in conjunction with medication. • They include – Reassurance and explanation – Use of fan or cool air across face – Adequate positioning of the patient to aid breathing – Breathing exercises and relaxation training – Advice on modifying lifestyle – Acupuncture, aromatherapy and reflexology Guidelines Pharmacological options Benzodiazepines (Level 3) • Benzodiazepines may be useful especially if there is coexisting anxiety and/or fear. • Lorazepam is suggested for episodes of paroxysmal breathlessness. Dose: 0.5mg-1mg sublingually as required (max dose 4mg daily). • In patients unable to tolerate oral medication or those in the dying phase, subcutaneous Midazolam 2.5mg-5mg as required may be appropriate. If effective this can be incorporated into a 24hour subcutaneous infusion via syringe driver. Guidelines Nebulised Medication (Level 4)/(Level 1) NB: The first medication of any nebulised medication, including saline, must be monitored for adverse effect such as bronchospasm. • Nebulised non opioids – Nebulised sodium chloride 0.9% may help as a mucolytic. Consider trial for 24hours. Dose: 5ml via a nebuliser 4 hourly as required. – A trial of nebulised bronchodilator should be considered if there is evidence of airways obstruction (Level 4) commonly prescribed bronchdilators are Salbutamol and Ipratropium Bromide.
    [Show full text]
  • Bahrain-Pharma-1444108170.Pdf
    Fill Type of Competition S. No BP Brand Name Therapeutical Class Potency Generic Name/Composition Volume Dosage Name,company, retail price form Each 5 ml contents: Samol 120 ml Salbutamol Sulphate 2mg Salbutamol 1 Anti-Asthmatic agent (Bronchodilator) Each 5ml contains Acefylline piperazine 125mg Pifalin 100 ml Acefylline Piperazine 2 (125mg/5ml) Acefylline Piperazine 45mg, Diphenhydramine Dephicef 100 ml Acefylline Piperazine + Diphenhydramine 3 8mg/5ml Ammonium Chloride 100.00mg , Sodium Clomadrin 100 ml Citrate 60.00mg, Ephedrine HCl 7.00mg, Ammonium Chloride + Sodium Citrate + Ephedrine HCl + Chlorpheniramine Maleate 4 Chlorpheniramine Maleate 2.00mg/5ml Each 5 ml contents: Ambroxol HCl eq. to 100 ml Ambroxol 15mg 5 Ambrol Ambroxol HCl Each 5 ml contents: Ambroxol HCl eq. to Cough and Cold 100 ml Syrup 6 Ambroxol 30mg 7 Dextron 100 ml 15mg/5 ml Dextromethorphan Hbr 8 Gufosil 100 ml 100mg/5 ml Guaifenesin 9 Proligen 120 ml 1.25mg + 30mg/5 ml Triprolodin HCl + Pseudoephedrine HCl 10 Tripodil 120 ml 1.25mg + 30mg + 10mg/5 ml Triprolodin HCL + Pseudoephedrine HCl + Dextromethorphan Hbr 11 Tripogin 120 ml 1.25mg + 30mg + 100 mg/5 ml Triprolodin HCL + Pseudoephedrine HCl + Guaifenesin 12 Dexotrin 120 ml 1.25mg +10mg + 7.5mg + 50mg/5 ml Triprolodin HCL + Pseudoephedrine HCl + Dextromethorphan Hbr + Guaifenesin Wild cherry (Prunus serotina) + (myroxylon balsamum) + Mallow (Malva Sylvestris) + Welcosin 120 ml 60mg + 18.75mg + 7.5mg + 7.5mg / 5ml 13 Marshnallow (Althaea officinalis) 14 Ivosil 100 ml Each 5 ml contents: Ivy leaf 15 Hexobim 100 ml 4mg/5mlIvy leaves dried extract (4-8:1, 100%) 100 mg Bromhexine HCl Carbocisteine 2% and 5% (i.e.
    [Show full text]
  • Disparities in Respiratory Health
    American Thoracic Society Documents An Official American Thoracic Society/European Respiratory Society Policy Statement: Disparities in Respiratory Health 6 Dean E. Schraufnagel, Francesco Blasi, Monica Kraft, Mina Gaga, Patricia Finn, Klaus Rabe This official statement of the American Thoracic Society (ATS) and the European Respiratory Society (ERS) was approved by the ATS Board of Directors, XXXXXXXXX, and by the ERS XXXXXXXX, XXXXXXXXXX [[COMP: Insert internal ToC]] 1 Abstract Background: Health disparities, defined as a significant difference in health between populations, are more common for diseases of the respiratory system than for those of other organ systems because of the environmental influence on breathing and the variation of the environment among different segments of the population. The lowest social groups are up to 14 times more likely to have respiratory diseases than are the highest. Tobacco smoke, air pollution, environmental exposures, and occupational hazards affect the lungs more than other organs and occur disproportionately in ethnic minorities and those with lower socioeconomic status. Lack of access to quality health care contributes to disparities. Methods: The executive committees of the American Thoracic Society (ATS) and European Respiratory Society (ERS) established a writing committee to develop a policy on health disparities. The document was reviewed, edited, and approved by their full executive committees and boards of directors of the societies. Results: This document expresses a policy to address health disparities by promoting scientific inquiry and training, disseminating medical information and best practices, and monitoring and advocating for public respiratory health. ERS and ATS have strong international commitments and work with leaders from governments, academia, and other organizations to address and reduce avoidable health inequalities.
    [Show full text]
  • Influence of Erdosteine, a Mucolytic Agent, on Amoxycillin Penetration Into Sputum in Patients with an Infective Exacerbation of Chronic Bronchitis
    Thorax: first published as 10.1136/thx.43.8.585 on 1 August 1988. Downloaded from Thorax 1988;43:585-590 Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis GIOVANNI RICEVUTI, ANTONINO MAZZONE, ELVIRA UCCELLI, GABRIELLA GAZZANI, GIANCARLO B FREGNAN From the Section ofMedical Pathology I, Department ofInternal Medicine and Therapeutics, University of Pavia; the Department ofPharmaceutical Chemistry, University ofPavia; and the Research Center Laboratories, Ednond Pharma SRL, Milan, Italy ABSTRACT Twenty four patients with acute infective exacerbations of chronic bronchitis received amoxycillin alone or in combination with erdosteine (a mucolytic agent) for a week in a double blind, placebo controlled study. Clinical assessment scores, body temperature, serum and sputum amoxycillin concentrations, and sputum culture results were recorded in each group. Erdosteine significantly increased antibiotic concentrations in sputum but not in serum. The combined treatment also caused a more rapid decrease in sputum viscosity and in body temperature and faster sterilisation of the sputum. These results show that erdosteine increases amoxycillin concentration in sputum in patients with acute exacerbations ofchronic bronchitis. This effect may be due to a reduction in the viscosity of the bronchial secretions produced by erdosteine. copyright. Introduction Methods Although the exact role ofbacterial infections in acute PATIENTS exacerbations of chronic bronchitis is not clear, Twenty four patients (10 male and 14 female, aged 45- antibiotic treatment is widely used. In some patients, 71 years) with chronic bronchitis were studied during http://thorax.bmj.com/ however, the high viscosity ofthe bronchial secretions an acute, severe infective exacerbation.
    [Show full text]
  • Erdosteine: Antitussive and Anti-Inflammatory Effects
    Lung (2008) 186 (Suppl 1):S70–S73 DOI 10.1007/s00408-007-9065-3 Erdosteine: Antitussive and Anti-inflammatory Effects Roberto W. Dal Negro Received: 31 July 2007 / Accepted: 4 October 2007 / Published online: 10 January 2008 Ó Springer Science+Business Media, LLC 2008 Abstract Erdosteine is a multifactorial drug currently used unresponsive to b2 adrenergics. This peculiar activity of in COPD for its rheologic activity on bronchial secretions erdosteine (to our knowledge never previously assessed) and its positive effects on bacterial adhesiveness. Erdosteine proved related to the ROS scavenging activity (which produces an active metabolite (Met 1) which was shown to actually proved equal to that of N), and its significant produce antioxidant effects during the respiratory burst of inhibiting effect on lipoperoxidation (8-isoprostane) proved human PMNs, due to the presence of an SH group. The discriminant between treatments, with antioxidant and anti- substantial antitussive effects of erdosteine were first docu- inflammatory effects the main determinants of the erdosteine mented in clinical trials even though mucolytic agents are multifactorial properties. In addition, antitussive effects may regarded as not consistently effective in ameliorating cough be regarded as related to its anti-inflammatory properties via in patients with bronchitis, although they may be of benefit to the improvement of mucociliary clearance and the reduction this population in other ways. Actually, a mucolytic drug of chemokines from epithelial cells. Finally, a sort of ‘‘sen- could exert antitussive effects if it also affects mucus con- sitization’’ of 2-adrenoceptors can also be speculated due to sistency and enhances ciliary function. In the last decade, the same mechanisms of action; if confirmed by further data from several studies on animal models pointed to the controlled studies, this particular property would suggest a possible antitussive and anti-inflammatory properties of novel therapeutic role of erdosteine in COPD.
    [Show full text]